Batch of executive changes at 4basebio
UK-based 4basebio (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, says it has promoted Christine Wolosin to chief commercial officer.
Ms Wolosin, who joined 4basebio in September 2025 as vice president, business development, will lead the company's global commercial strategy, business development initiatives, and customer engagement as the company scales its innovative synthetic DNA platform to serve the rapidly growing cell and gene therapy, mRNA, and vaccine markets.
The promotion follows the appointment of Dr Amy Walker as chief executive (CEO), replacing Dr Heikki Lanckriet. The two will work closely to execute 4basebio’s accelerated commercial growth strategy, focusing on deepening penetration of the synthetic DNA market as customers seek alternatives to plasmid DNA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze